Diagnosing multiple myeloma
Multiple myeloma can be easily overlooked due to nonspecific and vague symptoms, such as fatigue and back and bone pain.1
With Labcorp as your partner, you can access simple, guideline-recommended blood tests for multiple myeloma that lead to earlier detection and expedite patient referrals for improved diagnosis. This can result in more optimal treatment options and better patient outcomes.
The average patient will see their primary care provider three times with signs and symptoms before multiple myeloma is suspected. This delay in diagnosis may explain why almost 30% of patients with multiple myeloma present in urgent care or emergency settings.2
With delays in diagnosis come worsening patient outcomes and clinical complications, including increased risk of3:
Early diagnosis and referrals to a hematologist/oncologist to initiate treatment are associated with better outcomes.
|Complication||0-3 months (Sample group 28)||3-6 months (Sample group size 21)||> 6 months (Sample group size 43)|
Spotting symptoms like bone pain, fatigue, bruising, bleeding and lab abnormalities (anemia, elevated creatinine, hypercalcemia, elevated total protein, etc.)1 is just the first step in diagnosing multiple myeloma. To help you find answers for your patients, Labcorp’s three multiple myeloma tests (serum protein electrophoresis [SPEP], serum free light chain [sFLC], serum immunofixation electrophoresis [sIFE]) provide accurate and sensitive detection of pathogenic markers of the disease.
Discover a primary care approach to confronting this deceptive cancer and making a difference with early diagnosis
At Labcorp, we offer a Multiple Myeloma Profile in one convenient order code for the three guideline-recommended tests (SPEP, sIFE and sFLC) to support the diagnosis of multiple myeloma and appropriate referral to hematology/oncology.
Identifying the symptoms of multiple myeloma can be challenging when the signs are nonspecific.
When you know which patient populations are most at risk, you can detect multiple myeloma sooner and, if needed, initiate treatment earlier.
Risk factors for multiple myeloma include1,4-5:
How to recognize signs and symptoms of multiple myeloma
Did you know?
Multiple myeloma incidence is >2 fold higher in African American
and Black people than in white people.4
|Multiple Myeloma Diagnostic Algorithm||% Diagnostic Sensitivity|
|Freelite® sFLC alone||97|
|SPEP, sFLC and sIFE||> 99|
To achieve high diagnostic sensitivity when testing for multiple myeloma and other plasma cell disorders, guidelines now recommend the use of sFLC testing in combination with SPEP and sIFE.6 Together, these assays demonstrate >99% diagnostic sensitivity for myeloma, setting your patients on the most reliable path to diagnosis.7
Historically, when diagnosing multiple myeloma, providers used SPEP alone to detect and measure monoclonal proteins.